X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Ranbaxy: 3QFY02 result analysis - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Oct 11, 2001

    Ranbaxy: 3QFY02 result analysis

    Ranbaxy has declared its results for 3QFY02. Sales have grown by more than 16%, beating our expectations of 14.5% growth. Operating margins have also improved by 60 basis points, more or less in line with our expectations.

    There was a sharp spurt in interest expenses, up by over 163%. This was due to the fact that interest expenses in the previous year were net of interest income. However, interest income dipped in the current quarter, as the company didn’t book any income from its subsidiary, Vidyut Investments that discontinued its stock market lending operations. Tax provision also grew considerably on the back of change in accounting policy on deferred taxation.

    (Rs m) 3QFY01 3QFY02 % Change
    Sales 4,759 5,535 16.3%
    Other Income 11 7 -36.4%
    Expenditure 3,973 4,591 15.6%
    Operating Profit (EBDIT) 786 944 20.1%
    Operating Profit Margin (%) 16.5% 17.1% 3.3%
    Interest 82 216 163.4%
    Depreciation 125 130 4.0%
    Profit before Tax 590 605 2.5%
    Extraordinary Income/Provisions   727  
    Provisions/Contigencies   (300)  
    Tax 59 141 139.0%
    Profit after Tax/(Loss) 531 891 67.8%
    Net profit margin (%) 11.2% 16.1%  
    No. of Shares (eoy) (m) 116 116  
    Diluted Earnings per share* 18.3 30.7  
    P/E (at current price) 35.8 21.4  
    (*- annualised)      

    Net profit leapfrogged by 68%, primarily on the back of a one-time income from the sale of 50% stake in Eli Lilly Ranbaxy Ltd. The company has booked a profit of Rs 727 m from this sale. The company has also provided for Rs 300 million as provision on its stock market lending/operations in Vidyut Investments, the investment arm of the company.

    While domestic sales grew by 9%, exports registered a healthy growth of 24%. In the domestic markets, the company continued its efforts to reduce its dependence on anti-infective segments by launching new products in anti-diabetic and NSAID (Non Steroidal Anti-inflammatory Drugs) segments. In the export business, the company continued its thrust on high margin formulation exports compared to bulk drugs. Formulations exports jumped by 56% fueled by the higher exports to USA and Western Europe. Ranbaxy also registered maiden sales of US$ 9m in Brazil in first nine months of operations.

    Ranbaxy’s US subsidiary Ohm Laboratories announced generic launch of Ibuprofen-Pseudoephedrine combination tablets across US markets. The combination is a generic version of Advil, a cold and sinus drug with a market size of around US$ 46 m. This was one of Ranbaxy’s successful first-to-file Para IV approvals (this entitles the company to have six-month marketing exclusivity). On a conservative basis, we expect net profit of US$ 3.5 m from this launch, spread over next six months.

    Going forward, Ranbaxy is all set to capture a larger pie of export formulations and generics market with a wide product basket and mature ANDA filings. Ranbaxy has the widest basket of 39 products targeted at the US generics market. Further, unlike other pharma companies, Ranbaxy has not restricted itself to the US markets and has positioned itself as an integrated player in the export markets. Again unlike others, Ranbaxy has invested huge sums in creating a direct presence in 25 countries across the globe through various subsidiaries. Apart from US, the company has identified UK, Brazil, China and Germany as its key markets.

    Further, Ranbaxy has filed ANDA's for Cefuroxime Axetil and Isotretinoin, (Para IV) for six month marketing exclusivity. If granted, this could be a big earning opportunity for the company as combined branded sales for both the drugs are in excess of US$ 1 bn. We expect the company to earn US$ 30 m and US$ 65 m from Cefuroxime and Isotretinoin respectively. The litigation for Cefuroxime Axetil is currently on in the US and the launch of the drug would depend on the outcome of the litigation. Read more on Cefuroxime Axetil Opportunity.

    Overall, the results have been satisfactory. We expect export momentum to continue going forward due to several developments as mentioned above. We maintain our estimates for sales target for FY02.

    Comparative Valuations
    Particulars CMP P/E (x)
    (Rs.) 2002E 2003E
    Ranbaxy 660 31 24
    Cipla 1026 24 19
    Dr.Reddy's 1857 21 16

     

     

    Equitymaster requests your view! Post a comment on "Ranbaxy: 3QFY02 result analysis". Click here!

      
     

    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    RANBAXY LAB SHARE PRICE


    Apr 1, 2015 (Close)

    TRACK RANBAXY LAB

    • Track your investment in RANBAXY LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks

    MARKET STATS